Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?

Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, Ruben Smith, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Pontus Tideman, Tomas Ohlsson, Jonas Jögi, Keith Johnson, Reisa Sperling, View ORCID ProfileVincent Dore, Colin L. Masters, Christopher Rowe, Denise Visser, Bart N.M. van Berckel, Wiesje M. van der Flier, Suzanne Baker, William J. Jagust, Heather J. Wiste, Ronald C. Petersen, Clifford R. Jack Jr., Oskar Hansson
doi: https://doi.org/10.1101/2022.05.23.22275241
Rik Ossenkoppele
1Lund University, Clinical Memory Research Unit, Lund, Sweden
2Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
3Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: r.ossenkoppele@amsterdamumc.nl oskar.hansson@med.lu.se
Alexa Pichet Binette
1Lund University, Clinical Memory Research Unit, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Groot
1Lund University, Clinical Memory Research Unit, Lund, Sweden
2Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
3Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruben Smith
1Lund University, Clinical Memory Research Unit, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olof Strandberg
1Lund University, Clinical Memory Research Unit, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Palmqvist
1Lund University, Clinical Memory Research Unit, Lund, Sweden
4Memory Clinic, Skåne University Hospital, Malmö, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Stomrud
1Lund University, Clinical Memory Research Unit, Lund, Sweden
4Memory Clinic, Skåne University Hospital, Malmö, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pontus Tideman
1Lund University, Clinical Memory Research Unit, Lund, Sweden
4Memory Clinic, Skåne University Hospital, Malmö, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas Ohlsson
5Department of Radiation Physics, Skåne University Hospital, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonas Jögi
6Skåne University Hospital, Department of Clinical Physiology and Nuclear Medicine, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith Johnson
7Department of Neurology, Massachusetts General Hospital, Harvard Medical School
8Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School
9Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School
10Department of Radiology, Massachusetts General Hospital, Harvard Medical School
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reisa Sperling
7Department of Neurology, Massachusetts General Hospital, Harvard Medical School
8Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School
9Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Dore
11The Australian e-Health Research Centre CSIRO Melbourne Victoria Australia
12Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vincent Dore
Colin L. Masters
13The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Rowe
12Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
13The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise Visser
3Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
14Department of Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart N.M. van Berckel
3Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
14Department of Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wiesje M. van der Flier
2Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
3Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
15Department of Epidemiology and Biostatistics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne Baker
16Lawrence Berkeley National Laboratory, Berkeley, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. Jagust
16Lawrence Berkeley National Laboratory, Berkeley, CA, USA
17Helen Wills Neuroscience Institute, UC Berkeley, Berkeley, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather J. Wiste
18Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald C. Petersen
19Department of Neurology, Mayo Clinic, Rochester, MN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifford R. Jack Jr.
20Department of Radiology, Mayo Clinic, Rochester, MN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oskar Hansson
1Lund University, Clinical Memory Research Unit, Lund, Sweden
4Memory Clinic, Skåne University Hospital, Malmö, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: r.ossenkoppele@amsterdamumc.nl oskar.hansson@med.lu.se
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer’s disease (AD) neuropathological hallmarks (i.e., amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multi-center amyloid and tau PET study (n=1325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A+) and tau PET positive (T+) in the medial temporal lobe (A+TMTL+) and/or in the neocortex (A+TNEO+) and compared them with A+T- and A-T-groups. Cox proportional hazard models showed a substantially increased risk for progression to mild cognitive impairment in the A+TNEO+ (Hazard ratio [HR]=19.2[95% confidence interval: 10.9-33.7]), A+TMTL+ (HR=14.6[8.1-26.4) and A+T-(HR=2.4[1.4-4.3]) groups vs the A-T-(reference) group. Linear mixed effect models indicated that the A+TNEO+ (β=-0.056±0.005, T=-11.55, p<0.001), A+TMTL+ (β=-0.024±0.005, T=-4.72, p<0.001) and A+T-(β=-0.008±0.002, T=-3.46, p<0.001) groups showed significantly faster longitudinal global cognitive decline compared to the A-T-(reference) group (all p<0.001). Evidence of advanced AD pathological changes provided by amyloid and tau PET is strongly associated with short-term (i.e., 3-5 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This project has received funding from the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation programme (grant agreement No. 949570, PI: Rik Ossenkoppele). Work at Lund University was supported by the Swedish Research Council (2016-00906), the Knut and Alice Wallenberg foundation (2017-0383), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinsons disease) at Lund University, the Swedish Alzheimer Foundation (AF-939932), the Swedish Brain Foundation (FO2021-0293), The Parkinson foundation of Sweden (1280/20), the Konung Gustaf V och Drottning Victorias Frimurarestiftelse, the Skane University Hospital Foundation (2020-O000028), Regionalt Forskningsstod (2020-0314) and the Swedish federal government under the ALF agreement (2018-Projekt0279). Acknowledgement is also made to the donors of the Alzheimers Disease Research, a program of the BrightFocus Foundation, for support of this research (A2021013F). APB is supported by a postdoctoral fellowship from the Fonds de recherche en Sante Quebec (298314). The precursor of 18F-flortaucipir was provided by AVID radiopharmaceuticals and the precursor of 18F-RO948 was provided by Roche. The precursor of 18F-flutemetamol was sponsored by GE Healthcare. The MCSA is supported by the National Institute on Aging, U01 AG006786, GHR and the Alzheimers Association. Research of Alzheimer center Amsterdam has been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer and Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). The funding sources had no role in the design and conduct of the study; in the collection, analysis, interpretation of the data; or in the preparation, review, or approval of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Written informed consent was obtained from all participants. For MSCA, this study was approved by institutional review boards at the Mayo Clinic and Olmsted Medical Center (both Rochester, MS, USA). For the BioFINDER-1 and BioFINDER-2 studies, ethical approval was given by the Regional Ethical Committee in Lund, Sweden. For BACS, the Institutional Review Board at Lawrence Berkeley National Laboratory and the University of California Berkeley approved the study. The AIBL study was approved by institutional ethics committees of Austin Health, St. Vincent's health, Hollywood Private Hospital and Edith Cowan University. For HABS, the protocol was approved by the Partners Human Research Committee. For ADC, the study protocol was approved by the Medical Ethics Review Committee of the Amsterdam UMC, location VU Medical center

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Shared first authors

  • ↵** Shared last authors

Data Availability

Due to the multicentric design of the study, access to individual participant data from each cohort would have to be made available through the PIs of the respective cohorts. Generally, anonymised data can be shared by request from qualified academic investigators for the purpose of replicating procedures and results presented in the article, as long as data transfer is in agreement with the data protection regulation at the institution and is approved by the local Ethics Review Board. Requests for data from the open-access part of HABS can be submitted to: https://habs.mgh.harvard.edu.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted May 25, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?
Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, Ruben Smith, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Pontus Tideman, Tomas Ohlsson, Jonas Jögi, Keith Johnson, Reisa Sperling, Vincent Dore, Colin L. Masters, Christopher Rowe, Denise Visser, Bart N.M. van Berckel, Wiesje M. van der Flier, Suzanne Baker, William J. Jagust, Heather J. Wiste, Ronald C. Petersen, Clifford R. Jack Jr., Oskar Hansson
medRxiv 2022.05.23.22275241; doi: https://doi.org/10.1101/2022.05.23.22275241
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?
Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, Ruben Smith, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Pontus Tideman, Tomas Ohlsson, Jonas Jögi, Keith Johnson, Reisa Sperling, Vincent Dore, Colin L. Masters, Christopher Rowe, Denise Visser, Bart N.M. van Berckel, Wiesje M. van der Flier, Suzanne Baker, William J. Jagust, Heather J. Wiste, Ronald C. Petersen, Clifford R. Jack Jr., Oskar Hansson
medRxiv 2022.05.23.22275241; doi: https://doi.org/10.1101/2022.05.23.22275241

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (551)
  • Anesthesia (135)
  • Cardiovascular Medicine (1751)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (655)
  • Epidemiology (10790)
  • Forensic Medicine (8)
  • Gastroenterology (585)
  • Genetic and Genomic Medicine (2938)
  • Geriatric Medicine (286)
  • Health Economics (532)
  • Health Informatics (1921)
  • Health Policy (833)
  • Health Systems and Quality Improvement (744)
  • Hematology (291)
  • HIV/AIDS (628)
  • Infectious Diseases (except HIV/AIDS) (12506)
  • Intensive Care and Critical Care Medicine (686)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2788)
  • Nursing (151)
  • Nutrition (432)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1460)
  • Ophthalmology (442)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (363)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2635)
  • Public and Global Health (5349)
  • Radiology and Imaging (1006)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (725)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)